OSIRIS THERAPEUTICS
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1992-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.osiris.com/
Clinical Trials
7
Active:0
Completed:4
Trial Phases
3 Phases
Phase 3:1
Phase 4:5
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 4
5 (71.4%)Not Applicable
1 (14.3%)Phase 3
1 (14.3%)Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers
Not Applicable
Completed
- Conditions
- Venous Leg Ulcer
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT03629236
- Locations
- 🇺🇸
Integral Clinical Trial Solutions, Doral, Florida, United States
🇺🇸SSH, Weymouth, Massachusetts, United States
TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers
Phase 4
Terminated
- Conditions
- Diabetic Foot Ulcers
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT02936115
TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers
Phase 4
Terminated
- Conditions
- Chronic Venous Leg Ulcers
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 7
- Registration Number
- NCT02936128
GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers
Phase 4
Completed
- Conditions
- Foot Ulcer, Diabetic
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 75
- Registration Number
- NCT02675855
Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers
Phase 3
Terminated
- Conditions
- Chronic Diabetic Foot Ulcers
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 108
- Registration Number
- NCT02571738
- Locations
- 🇺🇸
SAVAHCS, Tucson, Arizona, United States
🇺🇸ILD Research Center, Carlsbad, California, United States
🇺🇸Center for Clinical Research, San Francisco, California, United States
- Prev
- 1
- 2
- Next
News
No news found